Skin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse eventsJune 14, 2019Immuno-oncologyImmunotherapy
EULAR issues guidelines on managing rheumatic complications of cancer immunotherapiesJune 14, 2019Immuno-oncologyImmunotherapy
R2 appears active in high-risk FL and MZLJune 14, 2019Lymphoma & Plasma Cell DisordersFollicular LymphomaRare Diseases
FDA approves trastuzumab-anns for HER2-positive breast, gastric cancerJune 14, 2019Breast CancerGastroenterologyGastrointestinal Cancer
Advanced basal cell carcinoma responds to pembrolizumab in proof-of-concept studyJune 13, 2019Nonmelanoma Skin Cancer
Triplet offers longest PFS yet seen in relapsed/refractory myelomaJune 12, 2019Lymphoma & Plasma Cell Disorders
PREDIX HER2 trial: Similar efficacy, less toxicity with T-DM1 for HER2+, HR+ breast cancerJune 12, 2019Breast Cancer
Four-drug combo bests triplet in newly diagnosed myelomaJune 12, 2019Lymphoma & Plasma Cell Disorders
Adding ipilimumab to nivolumab provides no benefit in SCC trialJune 12, 2019Lung CancerImmuno-oncology
KRISTINE: Three-year data help forge path to T-DM1-based deescalation in HER2+ BCJune 12, 2019Breast Cancer
Antibody targeting ‘do not eat me’ signals is active in AML, MDSJune 11, 2019Leukemia, Myelodysplasia, Transplantation
